Studies on GnRH Agonist Suppression of Estrogen Production in Patients with Endometriosis.

Shirou Ohtsuka, S Ohtsuka, Naoki Terakawa, N Terakawa, I Shimizu, Ikuya Shimizu, Masahiro Sakata, M Sakata, T Mizutani, Takahiro Mizutani, Akira Miyake, A Miyake, Osamu Tanizawa, O Tanizawa, T Aono, Toshihiro Aono
Endocrinologia japonica · 1989 · vol. 36(4) , pp. 611–619 · doi:10.1507/endocrj1954.36.611 · PMID:2510993 · W2027305377
article OA: bronze CC0 ⤵ 3 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

GnRH agonist treatment suppressed estrogen production in endometriosis patients by reducing bioactive LH and LH pulses, not by directly inhibiting ovarian estrogen synthesis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-14 · read from full text ⓘ

The paper investigated the mechanism by which chronic administration of a GnRH agonist suppresses ovarian estrogen production in women with endometriosis, using intranasal buserelin. During treatment, serum estradiol-17β levels were suppressed to near-castrate concentrations, while serum immunoreactive LH and FSH levels did not change, but bioactive LH was markedly reduced. The study also found disappearance of pituitary LH pulses and a significantly suppressed pituitary response to exogenous GnRH, while ovarian responsiveness to human menopausal gonadotropin remained unaltered. This paper is centrally about endometriosis — it specifically examines how GnRH agonist therapy suppresses estrogen production in patients with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The chronic administration of GnRH agonists to women results in the reversible suppression of estrogen production by the ovary. In the present study, the mechanism of the GnRH agonist suppression of estrogen production was investigated in patients with endometriosis. During the treatment with intranasal buserelin spray, the concentration of serum estradiol-17 beta (E2) was suppressed to near-castrate levels. Despite this marked suppression of serum E2, immunoreactive LH and FSH levels in serum were not changed. On the other hand, serum bioactive LH was markedly reduced. It was also observed during the treatment that the pituitary LH pulse disappeared and pituitary response to exogenous GnRH was significantly suppressed. In contrast, ovarian response to human menopausal gonadotropin (hMG) was not altered during the treatment. These findings suggest that the GnRH agonist suppression of estrogen production in the patients with endometriosis is through both suppression of the secretion of biologically active LH and the reduction of the LH pulse, but not through a direct inhibitory effect on ovarian estrogen biosynthesis.
Full text 1,314 characters · extracted from oa-doi-fallback · click to expand
Studies on GnRH Agonist Suppression of Estrogen Production in Patients with Endometriosis 1989 Volume 36 Issue 4 Pages 611-619 Details Abstract The chronic administration of GnRH agonists to women results in the reversible suppression of estrogen production by the ovary. In the present the mechanism of the GnRH agonist suppression of estrogen production investigated in patients with endometriosis. During the treatment with intranasal buserelin spray, the concentration of serum estradiol-17β(E2) was suppressed to near-castrate levels. Despite this marked suppression of serum immunoreactive LH and FSH levels in serum were not changed. On the hand, serum bioactive LH was markedly reduced. It was also observed the treatment that the pituitary LH pulse disappeared and pituitary response to exogenous GnRH was significantly suppressed. In contrast, ovarian response to human menopausal gonadotropin (hMG) was not altered the treatment. These findings suggest that the GnRH agonist suppression of estrogen production in the patients with endometriosis is through suppression of the secretion of biologically active LH and the reduction the LH pulse, but not through a direct inhibitory effect on ovarian estrogen biosynthesis. © The Japan Endocrine Society Favorites & Alerts Recently viewed articles Successor

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Estradiol Administration, Intranasal Adult Buserelin Buserelin Endometriosis Endometriosis Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone Luteinizing Hormone Radioimmunoassay

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Cited by (3)

References (21)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-16T06:07:01.518242+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
License: CC0 · commercial use OK